CD19 and myeloid leukemia: If such stability engineering were combined with affinity engineering to further increase the “selectivity window”, then later-stage versions of 33-3-19 may become potent and clinically useful therapeutic agents for a selective targeting of CD19+ CD33+ B/myeloid leukemia cells.